These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37997952)

  • 21. Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure.
    Chen R; Wan J; Song J; Qian Y; Liu Y; Gu S
    Pharm Biol; 2017 Dec; 55(1):503-509. PubMed ID: 27937122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.
    Bhalla K; Hwang BJ; Choi JH; Dewi R; Ou L; Mclenithan J; Twaddel W; Pozharski E; Stock J; Girnun GD
    J Biol Chem; 2011 Dec; 286(48):41626-41635. PubMed ID: 21979952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An
    Roxas JDP; San Juan MAD; Villagracia ARC; Espiritu RA
    J Biomol Struct Dyn; 2024 Jan; ():1-14. PubMed ID: 38189304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancing insulin sensitivity by dual PPARγ partial agonist, β-catenin inhibitor: Design, synthesis of new αphthalimido-o-toluoyl2-aminothiazole hybrids.
    Mourad AAE; Mourad MAE
    Life Sci; 2020 Oct; 259():118270. PubMed ID: 32814067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Modeling Study for the Design of Novel Peroxisome Proliferator-Activated Receptor Gamma Agonists using 3D-QSAR and Molecular Docking.
    Jian Y; He Y; Yang J; Han W; Zhai X; Zhao Y; Li Y
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29473866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.
    Choi SS; Kim ES; Koh M; Lee SJ; Lim D; Yang YR; Jang HJ; Seo KA; Min SH; Lee IH; Park SB; Suh PG; Choi JH
    J Biol Chem; 2014 Sep; 289(38):26618-26629. PubMed ID: 25100724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ by core hopping of telmisartan.
    Zhang J; Liu X; Wang SQ; Liu GY; Xu WR; Cheng XC; Wang RL
    J Biomol Struct Dyn; 2017 Sep; 35(12):2665-2680. PubMed ID: 27602589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain.
    Amato AA; Rajagopalan S; Lin JZ; Carvalho BM; Figueira AC; Lu J; Ayers SD; Mottin M; Silveira RL; Souza PC; Mourão RH; Saad MJ; Togashi M; Simeoni LA; Abdalla DS; Skaf MS; Polikparpov I; Lima MC; Galdino SL; Brennan RG; Baxter JD; Pitta IR; Webb P; Phillips KJ; Neves FA
    J Biol Chem; 2012 Aug; 287(33):28169-79. PubMed ID: 22584573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multi-conformational frame from molecular dynamics as a structure-based pharmacophore model for mapping, screening and identifying ligands against PPAR-γ: a new protocol to develop promising candidates.
    Prabitha P; Shanmugarajan D; Kumar TDA; Kumar BRP
    J Biomol Struct Dyn; 2022 Apr; 40(6):2663-2673. PubMed ID: 33140698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
    Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro.
    Burgermeister E; Schnoebelen A; Flament A; Benz J; Stihle M; Gsell B; Rufer A; Ruf A; Kuhn B; Märki HP; Mizrahi J; Sebokova E; Niesor E; Meyer M
    Mol Endocrinol; 2006 Apr; 20(4):809-30. PubMed ID: 16373399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mode of peroxisome proliferator-activated receptor γ activation by luteolin.
    Puhl AC; Bernardes A; Silveira RL; Yuan J; Campos JL; Saidemberg DM; Palma MS; Cvoro A; Ayers SD; Webb P; Reinach PS; Skaf MS; Polikarpov I
    Mol Pharmacol; 2012 Jun; 81(6):788-99. PubMed ID: 22391103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and pan-PPAR partial agonists.
    Liberato MV; Nascimento AS; Ayers SD; Lin JZ; Cvoro A; Silveira RL; Martínez L; Souza PC; Saidemberg D; Deng T; Amato AA; Togashi M; Hsueh WA; Phillips K; Palma MS; Neves FA; Skaf MS; Webb P; Polikarpov I
    PLoS One; 2012; 7(5):e36297. PubMed ID: 22649490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural design and synthesis of arylalkynyl amide-type peroxisome proliferator-activated receptor γ (PPARγ)-selective antagonists based on the helix12-folding inhibition hypothesis.
    Ohashi M; Gamo K; Tanaka Y; Waki M; Beniyama Y; Matsuno K; Wada J; Tenta M; Eguchi J; Makishima M; Matsuura N; Oyama T; Miyachi H
    Eur J Med Chem; 2015 Jan; 90():53-67. PubMed ID: 25461311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities.
    Einstein M; Akiyama TE; Castriota GA; Wang CF; McKeever B; Mosley RT; Becker JW; Moller DE; Meinke PT; Wood HB; Berger JP
    Mol Pharmacol; 2008 Jan; 73(1):62-74. PubMed ID: 17940191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a potential SARS-CoV2 inhibitor via molecular dynamics simulations and amino acid decomposition analysis.
    Razzaghi-Asl N; Ebadi A; Shahabipour S; Gholamin D
    J Biomol Struct Dyn; 2021 Oct; 39(17):6633-6648. PubMed ID: 32705953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
    Schopfer FJ; Cole MP; Groeger AL; Chen CS; Khoo NK; Woodcock SR; Golin-Bisello F; Motanya UN; Li Y; Zhang J; Garcia-Barrio MT; Rudolph TK; Rudolph V; Bonacci G; Baker PR; Xu HE; Batthyany CI; Chen YE; Hallis TM; Freeman BA
    J Biol Chem; 2010 Apr; 285(16):12321-33. PubMed ID: 20097754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a novel selective PPARγ ligand with a unique binding mode and improved therapeutic profile in vitro.
    Yi W; Shi J; Zhao G; Zhou XE; Suino-Powell K; Melcher K; Xu HE
    Sci Rep; 2017 Jan; 7():41487. PubMed ID: 28128331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Computational Drug Design Approaches for the Identification of Novel Antidiabetic Compounds from Natural Resources through Molecular Docking, ADMET, and Toxicological Studies.
    Akter B; Uddin MS; Islam MR; Ahamed KU; Aktar MN; Hossain MK; Salamatullah AM; Bourhia M
    Cell Biochem Biophys; 2024 Oct; ():. PubMed ID: 39377980
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.